AAPL343.75+1.75 (+0.51%) ▲|ABBV284.01+0.66 (+0.23%) ▲|ABT105.38+0.70 (+0.67%) ▲|ACN225.52+0.60 (+0.27%) ▲|ADBE249.76-1.91 (-0.76%) ▼|AMAT421.43-8.58 (-2.00%) ▼|AMD542.63-19.61 (-3.49%) ▼|AMGN437.85+3.82 (+0.88%) ▲|AMT183.39+2.03 (+1.12%) ▲|AMZN253.21-1.55 (-0.61%) ▼|AVGO338.43-5.91 (-1.71%) ▼|AXP319.10+5.23 (+1.67%) ▲|BA191.52+2.79 (+1.48%) ▲|BAC52.32+0.62 (+1.20%) ▲|BKNG166.32+0.52 (+0.31%) ▲|BLK1,139.18+18.40 (+1.64%) ▲|BMY60.81+0.24 (+0.39%) ▲|BNY143.80+1.71 (+1.20%) ▲|BRK-B531.42+5.74 (+1.09%) ▲|C125.85+2.64 (+2.14%) ▲|CAT738.06+2.42 (+0.33%) ▲|CL93.65+0.98 (+1.06%) ▲|CMCSA22.08+0.31 (+1.42%) ▲|COF203.55+4.69 (+2.36%) ▲|COP144.26+2.53 (+1.79%) ▲|COST987.72+9.71 (+0.99%) ▲|CRM241.89-4.85 (-1.97%) ▼|CSCO108.03-1.82 (-1.66%) ▼|CVS93.09+0.51 (+0.55%) ▲|CVX222.46+3.14 (+1.43%) ▲|DE649.95-0.73 (-0.11%) ▼|DHR229.74-1.76 (-0.76%) ▼|DIS111.50+0.82 (+0.74%) ▲|DUK120.54+1.66 (+1.39%) ▲|EMR162.67+0.52 (+0.32%) ▲|FDX297.57+2.03 (+0.69%) ▲|GD344.02+6.99 (+2.07%) ▲|GE319.62+7.62 (+2.44%) ▲|GEV933.59+7.15 (+0.77%) ▲|GILD156.90-0.47 (-0.30%) ▼|GM85.23+1.57 (+1.88%) ▲|GOOG340.26-4.65 (-1.35%) ▼|GOOGL344.13-5.09 (-1.46%) ▼|GS899.30+8.02 (+0.90%) ▲|HD312.61+4.37 (+1.42%) ▲|HON211.78+1.28 (+0.61%) ▲|IBM233.52-0.60 (-0.26%) ▼|INTC92.34-3.03 (-3.18%) ▼|INTU326.59-3.58 (-1.08%) ▼|ISRG433.29+5.43 (+1.27%) ▲|JNJ257.34+4.06 (+1.60%) ▲|JPM342.06+6.53 (+1.95%) ▲|KO93.37+1.37 (+1.48%) ▲|LIN500.24+7.02 (+1.42%) ▲|LLY1,265.23+13.62 (+1.09%) ▲|LMT546.01+13.37 (+2.51%) ▲|LOW198.43+2.71 (+1.38%) ▲|LRCX270.92-6.55 (-2.36%) ▼|MA620.09+3.77 (+0.61%) ▲|MCD243.80+1.30 (+0.53%) ▲|MDLZ64.06+1.03 (+1.63%) ▲|MDT95.63+0.18 (+0.19%) ▲|META726.33-10.39 (-1.41%) ▼|MMM167.05+1.72 (+1.04%) ▲|MO74.86+1.02 (+1.38%) ▲|MRK147.21+2.02 (+1.39%) ▲|MS182.90+0.80 (+0.44%) ▲|MSFT535.99-3.45 (-0.64%) ▼|MU893.37-37.87 (-4.07%) ▼|NEE80.08+1.12 (+1.42%) ▲|NFLX71.06-1.56 (-2.14%) ▼|NKE37.61+0.47 (+1.27%) ▲|NOW145.95-2.63 (-1.77%) ▼|NVDA216.23-1.00 (-0.46%) ▼|ORCL131.80-2.67 (-1.99%) ▼|PEP130.37+1.99 (+1.55%) ▲|PFE29.56+0.12 (+0.41%) ▲|PG159.63+2.55 (+1.62%) ▲|PLTR194.95-5.55 (-2.77%) ▼|PM204.33+4.43 (+2.21%) ▲|QCOM174.35-4.05 (-2.27%) ▼|RTX190.95+4.00 (+2.14%) ▲|SBUX97.01+0.13 (+0.13%) ▲|SCHW93.83-0.33 (-0.35%) ▼|SO90.12+0.94 (+1.05%) ▲|SPG205.58+2.19 (+1.08%) ▲|T23.56+0.06 (+0.23%) ▲|TMO691.51-4.98 (-0.72%) ▼|TMUS158.75+1.72 (+1.10%) ▲|TSLA366.61+4.17 (+1.15%) ▲|TXN280.91+1.79 (+0.64%) ▲|UBER71.22-0.05 (-0.07%) ▼|UNH397.50-9.17 (-2.25%) ▼|UNP289.48+0.77 (+0.27%) ▲|UPS99.15+1.32 (+1.35%) ▲|USB58.62+1.23 (+2.13%) ▲|V403.07+3.32 (+0.83%) ▲|VZ44.66+0.26 (+0.57%) ▲|WFC84.08+1.33 (+1.61%) ▲|WMT118.83+0.96 (+0.81%) ▲|XOM175.92+1.24 (+0.71%) ▲|AAPL343.75+1.75 (+0.51%) ▲|ABBV284.01+0.66 (+0.23%) ▲|ABT105.38+0.70 (+0.67%) ▲|ACN225.52+0.60 (+0.27%) ▲|ADBE249.76-1.91 (-0.76%) ▼|AMAT421.43-8.58 (-2.00%) ▼|AMD542.63-19.61 (-3.49%) ▼|AMGN437.85+3.82 (+0.88%) ▲|AMT183.39+2.03 (+1.12%) ▲|AMZN253.21-1.55 (-0.61%) ▼|AVGO338.43-5.91 (-1.71%) ▼|AXP319.10+5.23 (+1.67%) ▲|BA191.52+2.79 (+1.48%) ▲|BAC52.32+0.62 (+1.20%) ▲|BKNG166.32+0.52 (+0.31%) ▲|BLK1,139.18+18.40 (+1.64%) ▲|BMY60.81+0.24 (+0.39%) ▲|BNY143.80+1.71 (+1.20%) ▲|BRK-B531.42+5.74 (+1.09%) ▲|C125.85+2.64 (+2.14%) ▲|CAT738.06+2.42 (+0.33%) ▲|CL93.65+0.98 (+1.06%) ▲|CMCSA22.08+0.31 (+1.42%) ▲|COF203.55+4.69 (+2.36%) ▲|COP144.26+2.53 (+1.79%) ▲|COST987.72+9.71 (+0.99%) ▲|CRM241.89-4.85 (-1.97%) ▼|CSCO108.03-1.82 (-1.66%) ▼|CVS93.09+0.51 (+0.55%) ▲|CVX222.46+3.14 (+1.43%) ▲|DE649.95-0.73 (-0.11%) ▼|DHR229.74-1.76 (-0.76%) ▼|DIS111.50+0.82 (+0.74%) ▲|DUK120.54+1.66 (+1.39%) ▲|EMR162.67+0.52 (+0.32%) ▲|FDX297.57+2.03 (+0.69%) ▲|GD344.02+6.99 (+2.07%) ▲|GE319.62+7.62 (+2.44%) ▲|GEV933.59+7.15 (+0.77%) ▲|GILD156.90-0.47 (-0.30%) ▼|GM85.23+1.57 (+1.88%) ▲|GOOG340.26-4.65 (-1.35%) ▼|GOOGL344.13-5.09 (-1.46%) ▼|GS899.30+8.02 (+0.90%) ▲|HD312.61+4.37 (+1.42%) ▲|HON211.78+1.28 (+0.61%) ▲|IBM233.52-0.60 (-0.26%) ▼|INTC92.34-3.03 (-3.18%) ▼|INTU326.59-3.58 (-1.08%) ▼|ISRG433.29+5.43 (+1.27%) ▲|JNJ257.34+4.06 (+1.60%) ▲|JPM342.06+6.53 (+1.95%) ▲|KO93.37+1.37 (+1.48%) ▲|LIN500.24+7.02 (+1.42%) ▲|LLY1,265.23+13.62 (+1.09%) ▲|LMT546.01+13.37 (+2.51%) ▲|LOW198.43+2.71 (+1.38%) ▲|LRCX270.92-6.55 (-2.36%) ▼|MA620.09+3.77 (+0.61%) ▲|MCD243.80+1.30 (+0.53%) ▲|MDLZ64.06+1.03 (+1.63%) ▲|MDT95.63+0.18 (+0.19%) ▲|META726.33-10.39 (-1.41%) ▼|MMM167.05+1.72 (+1.04%) ▲|MO74.86+1.02 (+1.38%) ▲|MRK147.21+2.02 (+1.39%) ▲|MS182.90+0.80 (+0.44%) ▲|MSFT535.99-3.45 (-0.64%) ▼|MU893.37-37.87 (-4.07%) ▼|NEE80.08+1.12 (+1.42%) ▲|NFLX71.06-1.56 (-2.14%) ▼|NKE37.61+0.47 (+1.27%) ▲|NOW145.95-2.63 (-1.77%) ▼|NVDA216.23-1.00 (-0.46%) ▼|ORCL131.80-2.67 (-1.99%) ▼|PEP130.37+1.99 (+1.55%) ▲|PFE29.56+0.12 (+0.41%) ▲|PG159.63+2.55 (+1.62%) ▲|PLTR194.95-5.55 (-2.77%) ▼|PM204.33+4.43 (+2.21%) ▲|QCOM174.35-4.05 (-2.27%) ▼|RTX190.95+4.00 (+2.14%) ▲|SBUX97.01+0.13 (+0.13%) ▲|SCHW93.83-0.33 (-0.35%) ▼|SO90.12+0.94 (+1.05%) ▲|SPG205.58+2.19 (+1.08%) ▲|T23.56+0.06 (+0.23%) ▲|TMO691.51-4.98 (-0.72%) ▼|TMUS158.75+1.72 (+1.10%) ▲|TSLA366.61+4.17 (+1.15%) ▲|TXN280.91+1.79 (+0.64%) ▲|UBER71.22-0.05 (-0.07%) ▼|UNH397.50-9.17 (-2.25%) ▼|UNP289.48+0.77 (+0.27%) ▲|UPS99.15+1.32 (+1.35%) ▲|USB58.62+1.23 (+2.13%) ▲|V403.07+3.32 (+0.83%) ▲|VZ44.66+0.26 (+0.57%) ▲|WFC84.08+1.33 (+1.61%) ▲|WMT118.83+0.96 (+0.81%) ▲|XOM175.92+1.24 (+0.71%) ▲|
17.3 C
New York
Friday, October 16, 2026

Tag: clinical trials

newssourceFORcompanycontentinformation1releasesmarket

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will...

Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation |...

The Pompe disease market is estimated to change significantly during the forecast period (2026–2036), owing to the launch of novel therapies including MZE001 (S-606001;...

TRI Launches TRIAL.OS: A New Operating System for Intelligent Clinical Trials

CAMBRIDGE, England, Oct. 13, 2026 /PRNewswire/ -- TRI, the experts in Risk-Based Quality Management (RBQM), today announced the launch of TRIAL.OS, a new operating...

Nationally Recognized Cardiac Surgeon Anthony D. Caffarelli, M.D., Joins MemorialCare as Chief of Cardiac Surgery, MemorialCare Heart & Vascular Institute

Southern California physician leader returns to Long Beach and Orange County, where his medical career began, to help advance cardiovascular care across MemorialCare. FOUNTAIN...

Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer

The HARNESS-1 Safety Review Committee identified no dose-limiting toxicities or treatment-related safety concerns in either Cohort 1 patient during the safety observation period and...

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for the Treatment of Advanced Prostate Cancer; Changchun GeneScience Pharmaceutical will Commercialize in China

TAIPEI, Oct. 12, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical...

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across...

Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn’s Disease and Ulcerative Colitis at ACG 2026

New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely...

First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer

HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a...

Stowers scientist selected for $28.6 million research effort to predict protein changes behind neurodegenerative disease

The new award brings together a team of scientists who will combine AI, large-scale experiments and human-cell studies to predict harmful protein changes before...

UCB Dedicates Site for New U.S. Biologics Manufacturing Campus in Georgia

Site dedication signals continued momentum for UCB's first U.S. manufacturing campusEmphasizes long-term commitment to advancing innovation, patient access, and workforce development in Gwinnett County and surrounding...

Hyundai Hope on Wheels makes $200,000 donation to bolster the fight against childhood cancer in Quebec

The Foundation CHUS Sherbrooke and the Montreal Children's Hospital Foundation received $100,000 each from the Hyundai Hope on Wheels.The grants, presented during two inspiring...

Blood Cancer United Presents Inaugural Breakthrough Voice and Breakthrough Rising Leader Awards at First-Ever Night of Champions

Dr. Siddhartha Mukherjee and Charlotte Nathanson honored during Blood Cancer United's Breakthroughs Summit in New York CityNEW YORK, Oct. 9, 2026 /PRNewswire/ -- Blood Cancer...

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trials

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers